Abstract: Node negative breast cancer is a prevalent form of breast cancer.With the improvement of breast cancer screening and disease awareness,the rates of node negative breast cancer are gradually increasing.Although node negative breast cancer patients have much lower recurrence rates as compared with node positive patients,node-negative breast cancer is unequal to a low risk disease.Thus,it is important for oncologist to estimate the risk factors of node negative disease,to carry out risk assessment and to guide the best regimen for these patients.In current review,we discuss the value of traditional prognostic factors and new prognostic factors,such as the urokinase-type plasminogen activator/plasminogen activator inhibitor 1,oncotype DX,MammaPrint and tumor associated macrophages,on the predictive and treatment decisions in node negative breast cancer.